The beta 2-adrenergic agonist terbutaline suppresses experimental allergic neuritis in Lewis rats.
Treatment of rats with experimental allergic neuritis with the beta 2-adrenergic agonist terbutaline suppresses clinical symptoms, decreases demyelination and Wallerian degeneration in peripheral nerves and improves electrophysiological parameters. Treatment is highly effective when given from the time of immunization through the acute phase of illness, when given for the first 12 days after immunization and also when given after the onset of the disease.
Kim
D H
DH
Department of Neurology, University of Chicago, IL 60637.
Muthyala
S
S
Soliven
B
B
Wiegmann
K
K
Wollmann
R
R
Chelmicka-Schorr
E
E
D000200:Action Potentials; D000818:Animals; D000242:Cyclic AMP / Q000032:analysis; D005260:Female; D009431:Neural Conduction; D009444:Neuritis, Autoimmune, Experimental / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D051381:Rats; D011917:Rats, Inbred Lew; D013726:Terbutaline / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D014409:Tumor Necrosis Factor-alpha; D000242:Cyclic AMP; D013726:Terbutaline